The first new drug therapy developed exclusively for CF in 30 years was approved by the Food and Drug Administration (FDA) in 1993. In clinical trials, this mucus-thinning drug called Pulmozyme, reduced the number of respiratory infections and improved lung function. In 1995, a four-year Foundation supported study showed that the drug, ibuprofen, reduced the rate of lung inflammation in children with CF under controlled conditions, and in high doses.

    In late 1997, the FDA approved the drug TOBI (tobramycin solution for inhalation). In clinical trials, this reformulated version of the common antibiotic improved lung function in people with CF and reduced the number of hospital stays. The benefits of TOBI are that it can be delivered in a more concentrated dose directly to the site of CF lung infections more efficiently, and that it is preservative-free. The development of TOBI should lead to a long line of other aerosolized antibiotics for people with CF.

    In addition, other treatment strategies to correct the protein product of the gene are currently being tested in clinical trials. What makes these drugs so unique is that researchers appear to be treating the causes of CF, not just the symptoms.

"Caring Hearts and Helping Hands"
YES! I want to support "America's Challenge Foundation" in their efforts to 
aid directly the families and children with Cystic Fibrosis....A beautiful silver certificate will be mailed to you showing you are a supporter of our foundation.

Help Us! To Help Others; Make Your Donation Today!
All donations must be made in the name of "America's Challenge Foundation". 


If your contribution is by check; please mail your check to:

America's Challenge Foundation
P.O. Box 890849
Oklahoma City, Oklahoma 73189-0849